AETERNUSPERFORMANCEJoin

CJC-1295 DAC

CJC-1295 DAC is a long-acting GHRH analog research topic with human GH/IGF-1 pharmacology and clear safety limits.

Evidence level
Early human data
Human studies
2
Total sources
5
Last reviewed
2026-06-03

Reviewed by Bryan Powell · editorial review, not medical review

GHRH signaling · GH axis · IGF-1 context

At a glance

CJC-1295 DAC has a more direct clinical pharmacology record than the no-DAC discussion, but it still belongs in an investigational endocrine context. The useful profile explains GHRH analog biology, drug-affinity-complex pharmacology, GH and IGF-1 signal changes, and why long-acting exposure should not become outcome language.

What CJC-1295 DAC is

CJC-1295 DAC is a modified GHRH(1-29)-based analog designed with a drug-affinity complex that binds to albumin and extends exposure. In plain terms, the DAC form is the long-acting version that appears in the core human CJC-1295 literature. That makes it distinct from CJC-1295 no DAC, which is usually discussed as modified GRF 1-29 without the albumin-binding extension.

Mechanism

Why It Shows Up in Long-Acting GHRH Discussions

The biological context centers on pituitary GHRH receptor signaling, GH pulsatility, IGF-1 response, albumin-binding pharmacology, and endocrine feedback. These systems are clinically meaningful but not casually controllable. Public content should keep the discussion in pharmacology and evidence context rather than body-composition, recovery, or longevity claims.

DAC Pharmacology, Without Turning Exposure Into a Promise

CJC-1295 DAC is discussed mechanistically as a long-acting GHRH analog. The DAC component supports extended exposure by linking the peptide to albumin-binding pharmacology, which changes the interpretation compared with no-DAC forms. The animal platform work and human clinical pharmacology papers support this as a distinct investigational compound.

The human literature shows GH and IGF-1 axis changes in controlled research settings and suggests GH pulsatility can persist during continuous stimulation. Those are important endocrine observations. They are not proof of practical outcomes, and they do not remove questions about safety, population fit, duration, or real-world product quality.

What the evidence actually shows

Human data

Direct human trial evidence among the reviewed sources.

The reviewed sources include human clinical pharmacology studies of DAC CJC-1295 in healthy adults. This supports limited human evidence for GH/IGF-1 axis changes and pulsatility context. It does not support broad practical or therapeutic claims.

Preclinical data

Animal or in-vitro work. Does not establish human effect.

Preclinical platform work supports the albumin-binding and GHRH analog mechanism. Animal and pharmacology findings help explain why the DAC form was developed, but they should not be treated as real-world human outcomes.

Anecdotal discussion

Reported experience. Not evidence of effect.

Anecdotal discussion around CJC-1295 DAC often focuses on duration, convenience, and stronger endocrine effects. That discussion can explain public interest, but it is not evidence of benefit or safety. It also increases the risk of confusing pharmacologic exposure with practical value.

Where people overreach

Human endpoints are narrow. GH and IGF-1 changes do not establish recovery, physique, sleep, or longevity outcomes.

Long-acting exposure creates uncertainty. Extended pharmacology may be scientifically useful while still raising safety and monitoring questions.

Not the no-DAC evidence base. DAC data should not be generalized to no-DAC entries, and no-DAC assumptions should not be imported back into DAC discussion.

Real-world product identity is unresolved. Published trials do not validate market materials or unsupervised use.

Safety and regulatory context

Regulatory status matters. FDA compounding-risk context for CJC-1295 supports caution around immunogenicity, peptide impurities, and product characterization.

Endocrine feedback matters. Long-acting GH-axis stimulation should not be simplified into benefit language.

Sport-governance context matters. Synthetic GHRH analogs appear in anti-doping and analytical literature, which supports careful public framing.

Practical interpretation

CJC-1295 DAC appears in performance and longevity discussions because long-acting GH-axis modulation sounds powerful. That framing can be misleading. Aeternus treats the compound as an investigational endocrine pharmacology topic with human data, not as an optimization tool.

The practical interpretation is to keep the claim attached to the source. Human studies can support GH and IGF-1 pharmacology discussion. They do not establish improved recovery, body composition, sleep, tissue repair, or aging outcomes.

What CJC-1295 DAC is not

Not CJC-1295 no DAC. DAC and no-DAC forms have different pharmacology and should not be merged.

Not an approved optimization compound. Human pharmacology does not equal broad medical, recovery, or longevity validation.

Not a guaranteed endocrine benefit. GH and IGF-1 signals require careful interpretation.

Aeternus position

Aeternus views CJC-1295 DAC as a serious endocrine research topic that deserves exact language. The human pharmacology is relevant, but the claim ceiling remains narrow. The right position is to explain DAC design, identify the studied endpoints, separate it from no-DAC discussion, and keep safety and regulatory context visible.

Regulatory status

Three separate questions, kept separate on purpose. Whether CJC-1295 DAC appears on FDA’s pharmacy-compounding list, whether an approved medicine containing it exists, and whether it is banned in sport are three different things, and the answer to one tells you nothing about the others.

FDA 503A bulk substances list

On neither list

Does not appear on FDA’s Category 1 or Category 2 bulk substances lists.

Left FDA Category 2 on or about 2026-04-22 because the nominators withdrew the nomination, not because FDA resolved its safety concerns. Those concerns remain published. FDA lists a single undifferentiated entry, 'CJC-1295', with no DAC distinction.

Primary source

Source directness: high — a named primary document states this outright

FDA approval

No FDA-approved product

Primary source

Source directness: high — a named primary document states this outright

WADA prohibited list

Prohibited at all times · S2.2.4 · named explicitly

Named among GHRH analogues: 'GHRH and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)'.

Primary source

Source directness: high — a named primary document states this outright

Verified against primary sources on 2026-07-31 · last regulatory change 2026-04-22

Regulatory status changes, sometimes quickly. This reflects what the primary sources said on the date above and nothing more. Verify before acting on it.

Sources (5)

  1. animal study · moderateHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogEndocrinology, 2005 · doi:10.1210/en.2004-1286
  2. human study · moderateProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJournal of Clinical Endocrinology & Metabolism, 2006 · doi:10.1210/jc.2005-1536
  3. human study · moderatePulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogJournal of Clinical Endocrinology & Metabolism, 2006 · doi:10.1210/jc.2006-1702
  4. review · moderateAdvances in the detection of growth hormone releasing hormone synthetic analogsDrug Testing and Analysis, 2021 · doi:10.1002/dta.3183
  5. regulatory · moderateCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA, 2026

Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.

Other compounds in Hormone & Growth Signaling